Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone

54Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

Abstract

Objective: To carefully examine the features of controlled ovarian stimulation performed with recombinant FSH-α or hMG. Design: Controlled, prospective, randomized comparison of fixed gonadotropin regimens. Setting: Academic research institution. Patient(s): Fifty infertile patients who were candidates for IUI. Intervention(s): Patients were randomized to receive a fixed regimen of recombinant FSH-α (150 IU/day, 25 patients) or hMG (150 IU/day, 25 patients), after GnRH-agonist suppression (long regimen). Main outcome measure(s): Daily measurements of serum LH, immunoreactive FSH, hCG, E2, P, and T. Transvaginal pelvic ultrasound every 2 days. Pregnancy and abortion rates. Cost of medications. Result(s): Two recombinant FSH-α-treated patients did not respond. Despite matched daily FSH dose, duration of treatment (hMG 10.8 ± 0.4 vs. recombinant FSH-α 12.4 ± 0.5 days), gonadotropin dose (21.7 ± 0.8 vs. 25.3 ± 1.3 ampoules), gonadotropin cost (288 ± 10 vs. 1,299 ± 66 €/cycle), serum P levels, and small preovulatory follicle number were significantly lower, and LH, hCG, immunoreactive FSH levels, and larger follicles on day 8 were significantly higher in hMG-treated patients. The pregnancy, abortion, and twin pregnancy rates did not differ. Conclusion(s): The hMG administration was associated with: [1] increased serum LH activity and immunoreactive FSH levels during treatment; [2] reduced signs of premature luteinization; [3] differential modulation of folliculogenesis; [4] lower treatment duration, gonadotropin dose, and cost; and [5] clinical outcome comparable to recombinant FSH-α. © 2003 by American Society for Reproductive Medicine.

Cite

CITATION STYLE

APA

Filicori, M., Cognigni, G. E., Pocognoli, P., Tabarelli, C., Ferlini, F., Perri, T., & Parmegiani, L. (2003). Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone. Fertility and Sterility, 80(2), 390–397. https://doi.org/10.1016/S0015-0282(03)00594-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free